Latest PolyPid News & Updates

See the latest news and media coverage for PolyPid. We track all announcements, press releases, and industry mentions in real time, all in one place.

PolyPid

Developer of long-acting controlled-release medicines

polypid.com

Headquarters: Petah Tikva, Israel
Company type: Public company
Number of employees: 10–80
Industry: Pharmaceuticals

Last updated Today

Latest news about PolyPid

In short: PolyPid completed its NDA submission to the FDA for D-PLEX100 and advanced clinical data presentations following positive Phase 3 results.

Company announcements

June 1 PolyPid

PolyPid completes NDA submission to FDA for D-PLEX100

The submission aims to prevent surgical site infections; PDUFA target in Q1 2027.

May 13 PolyPid

PolyPid reports Q1 2026 results and updates on NDA submission

Initiated rolling NDA submission for D-PLEX100 to FDA, advanced EU regulatory preparation, and reported net loss of $7.7 million. Cash and equivalents totaled $10.9 million.

March 31 PolyPid

PolyPid initiates NDA submission to FDA for D-PLEX100

The rolling submission includes CMC and nonclinical modules, with completion expected in Q2 2026.

March 17 PolyPid

PolyPid receives PDUFA fee waiver from FDA for D-PLEX100

The $4.3M waiver enables focus on commercialization; NDA submission initiation is on track for March.

Media coverage

July 12 Stockhouse

PolyPid Secures $15 Million Non-Dilutive Secured Term Loan Facility

PETACH TIKVA, Israel, April 06, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid&CloseCurlyDoubleQuote; or the “Company&CloseCurlyDoubleQuote;), a late-stage biopharma company aiming to improve surgical...

June 26 The Globe and Mail

Lilly's $780M Bet is Reshaping Surgical Infection Prevention, and PolyPid's Asset is Hiding in Plain Sight

A May 2026 Big Pharma acquisition just validated the surgical site infection prevention market at the highest possible level. PolyPid (NASDAQ:PYPD) recently completed its NDA...

June 1 The Globe and Mail

PolyPid Files NDA with FDA for Lead Infection-Prevention Drug D-PLEX100

Discover high-conviction stock picks and new investing opportunities with the TipRanks Smart Investor Newsletter PolyPid ( (PYPD)) just unveiled an update. On June 1, 2026...

February 1 Yahoo Finance

PolyPid Ltd. Q4 2025 Earnings Call Summary

PolyPid Ltd. Q4 2025 Earnings Call Summary - Moby Strategic Execution and Operational Evolution Successfully completed the SHIELD II Phase III trial for...

Never miss news about PolyPid

Track PolyPid and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

PolyPid competitors & trending companies

Browse news for competitors to PolyPid and other trending companies.